anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises sulphonyl ureas of the formula <FORM:1089197/C2/1> and their physiologically tolerable salts, wherein R1 is a C1- 8 alkyl, C5- 8 cycloalkyl or ((C5- 8 cycloalkyl)-alkyl group having 1-3 carbon atoms in the alkyl portion, X is a hydrocarbon group of 1 or 2 carbon atoms, e.g. methylene, ethylene, ethenylene or ethylidene and R2 is (a) a C2- 8 alkyl group, (b) a phenyl-C1- 3 alkyl or cyclohexyl-C1- 3 alkyl group, (c) an endoalkylenecyclohexyl, -cyclohexenyl, -cyclohexylmethyl or -cyclohexenylmethyl group containing 1 or 2 endoalkylene carbon atoms, (d) a C1- 4-alkylcyclohexyl group, or (e) a C5- 8 cycloalkyl group. The compounds are prepared by (a) reaction of an R1OOC.X- substituted benzenesulphonamide (suitably in the form of a salt) with an isocyanate R2CNO or a corresponding carbamic acid ester or halide, thiocarbamic ester, urea or N2-substituted urea, (b) reaction of an amine R2NH2 or a salt thereof with a benzenesulphonyl urea isocyanate, R1OOC.X.C6H4.SO2-NCO or a corresponding carbamic ester or halide, thiocarbamic ester, urea or N2-substituted urea, (c) reaction of a benzenesulphonyl chloride R1OOC.X.C6H4.SO2Cl with an R2 substituted urea, isourea ether, isothiourea ether or parabanic and hydrolysis of a benzenesulphonyl isourea ether, isothiourea ether or parabanic acid obtained in this way or by another method, (d) exchange of the sulphur atom in a corresponding benzenesulphonylthiourea for an oxygen atom by oxidation or reaction with a heavy metal salt, and (e) oxidation of a corresponding benzenesulphenyl or benzenesulphinyl urea.  If desired, carboxylic acids HOOC.X.C6H4.SO2.NH.CO.NHR2 formed by the above reactions or in another way may be esterified to introduce the group R1. Alternatively a compound wherein X is -CH = CH- may be hydrogenated to form a product wherein X is -CH2-CH2-.  4 - Sulphamoyl - phenylacetic acid is made by chlorosulphonating phenylacetic acid and reacting the resulting acid chloride with ammonia.  N - (4 - Carbo - n - butoxy - methyl - benzenesulphonyl)-urea is made by the action of potassium cyanate on the corresponding benzenesulphonamide. 4 - b  - Carbethoxyvinyl - benzenesulphonamide is made by esterifying the free acid.  N - 4 - Carbethoxymethyl - benzenesulphonyl - N1-cyclohexyl-urea is made by the action of chloroformic methyl ester on the corresponding sulphonamide.  Pharmaceutical preparations for the treatment of diabetes comprise the above compounds of the invention in admixture or conjunction with a carrier, preferably in a form suitable for oral administration such as tablets.
The recommendation for the treatment of suicidal adolescents, Cognitive Behavioral Therapy (CBT) targeted new generation offer effective approaches to suicidal crisis and relapse prevention.

Since 2009, our team is engaged in a partnership between France and Quebec Interuniversity agreement concluded by a University Picardie Jules Verne-University of Montreal. In this context, two teams G4 (Amiens and Rouen) have received training in suicidal crisis, including the security plan by a university instructor and TCC Québec, Dr. Labelle. Furthermore, we complete a descriptive and prospective study of risk and protective factors for adolescent suicide in which the Quebec team of Professor Labelle contributes as an expert (sponsor: Rouen). 200 subjects were recruited on 2 years by 3 (CHU Amiens, CH Compiègne, CHU Rouen) with an assessment of recurrence at 1 year (lost rates of view = 15%). The first results highlight the central role of personal coping strategies (coping) in suicidal recurrence. We want extend this study to validate the implementation of the security plan (safety level) with suicidal adolescents. The security plan is the initial step of the TCC approach short of suicidal crisis. It is established after working with adolescents and their families (chain analysis of the suicidal crisis, coping self-evaluation and identification of support resources). Developed by Stanley B from Columbia University and adapted for francophone adolescents R Labelle and JJ Breton wrote this list those resources and coping strategies to apply in case ideation and suicidal crisis. Signed by the young person and his family, he then uses to frame the monitoring and management plan of the youth and his family environment, friendly and professional in case of suicidal crisis.
Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W).
The present invention relates to a peel-off-type rubber pack composition having a self-restoring gel form, and a method for producing the same. The present invention relates to a peel-off-type cosmetic composition containing a film-forming polymer in an aqueous part thereof. To impart molding properties to the film-forming polymer, a self-restoring gel form is ensured by a polymer matrix formed by adding a bivalent or trivalent cationic metal salt. A wax-borax emulsion is disposed by emulsifying used wax by borax to provide a peel-off pack having a thickness of 3 mm or more after being coated on the polymer matrix. Accordingly, a cushioning effect, usage convenience, and thick and excellent moisturization are ensured. In addition, compared to a 2-formualtion conventional cosmetic composition of a powder and a liquid or a liquid and a liquid, a 1-formulation peel-off-type rubber pack composition is provided, so usability is improved. Also, the market of rubber packs can be widened to a general mass market.
To err is human. Most errors are caused by problems in the system. Punishing health personnel cannot prevent the same mistakes. The only solution is a good medication system. CPOE system can prevent prescribing errors. The CPOE system is always the major step in some studies concerning reducing prescribing errors, dispensing errors or administering errors. In this user-friendly and convenient era, improvement in the CPOE system is an immediate need.
Nail hardening compsn giving good absorption and finish comprises a pref. 5-10 wt.% soln of the iodide of a terpene (pref. limonene, beta-pinene, sylvestrine, beta-terpinene or beta-phellandrene) in na essential oil (pref. extract of conifer, hesperidin or labiate). The iodide, of formula C10H16I2, is made by controlled addition of I2, with cooling if necessary to a soln. of the terpene in the oil, to give the necessary degree of combined I.
The invention discloses a high-activity amylase inhibition active peptide, the sequence of which is shown as SEQ ID NO. 1: met-Met-Phe-Pro-His. The high-activity amylase inhibition active peptide provided by the invention has good amylase inhibition activity. The active peptide of the present invention binds to each other through a suitable orientation and amino acid residues on the amylase, simultaneously with binding sites on the amylase, including the active site and amino acid residues near the active site; the binding pattern of the active peptide to amylase is shown to be rapid binding but slow dissociation. The combined action mode can inhibit amylase activity and prolong hydrolysis time of starch. The invention also provides a preparation method of the high-activity amylase-inhibiting active peptide, which is prepared from quinoa by separation, and has the advantages of wide raw material sources and easy operation and realization of the preparation process. The invention also provides application of the high-activity amylase inhibiting active peptide, which can be used as an amylase activity inhibitor in health-care products, foods or medicines.
In Waldenström's macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas. Thus innovative approaches are needed which combine excellent activity and tolerability in patients with WM, who are mostly of advanced age. Today, chemotherapy in combination with the anti-cluster of differentiation (CD) 20 antibody rituximab is still the backbone of treatment in patients with WM and is recommended as first line in national and international treatment guidelines. With the approval of Ibrutinib by the European Medicines Agency (EMA) 2015 for patients with relapsed WM or for patients not eligible for chemotherapy with treatment naïve WM treatment landscape has changed in this lymphoma subtype and there is an urgent need to evaluate to which extent chemotherapy-free approaches add clinical benefit to the patient. The treatment in the "European Consortium for Waldenström's Macroglobulinemia" (ECWM)-2 trial will test, whether the chemotherapy-free approach, which is given orally (ibrutinib) and subcutaneously (bortezomib and rituximab from cycle 2 onwards) (B-RI) will approach the efficacy of chemotherapy containing treatment concepts, but avoids chemotherapy associated toxicity. From the perspective of single agent ibrutinib, this regimen tests whether ibrutinib can be further optimized by adding rituximab and bortezomib. The combination of rituximab and ibrutinib was tested in comparison to rituximab/placebo in a large international phase III trial on behalf of the European Consortium for Waldenström's Macroglobulinemia in relapsed and first line WM, and results were recently published: in this trial no unexpected toxicity of the combination ibrutinib/rituximab was reported. Furthermore, ibrutinib/rituximab was significantly superior to rituximab/placebo with regard to response rates and PFS. From the perspective of the established rituximab/bortezomib regimen, the combination of B-RI will evaluate whether adding ibrutinib to this combination will add any benefit for the patient.

To this end, the aim of the study is to assess the toxicity and efficacy of B-RI in an exploratory phase II trial.
Abstract of the Invention The method of etching a porcelain dental appliance insi-tu including the steps of contacting the porcelain with a buffered solution containing trace amounts of hydrogen fluoride and removing the solution after sufficient time has elapsed to allow the porcelain to be etched.  Preferred so lutions are buffered at a pH from about 2.0 to about 6.0 and most preferably from about 3.5 to about 4.5  Contact time of the solution with porcelain ranges from about five minutes to from about five to about thirty minutes or longer.    The solution preferably contains an alkali metal fluo-ride dissolved in a weak acid.  In a preferred embodiment, the solution contains about one to about three parts by weight of sodium fluoride dissolved in about 50 parts to about 150 parts by weight of dilute weak acid.  The weak acid has a molarity of from about 0.05 molar to about 0.5 molar.          The weak acid solution is buffered, if necessary, and has a pH of from about 2.0 to about 6.0 and preferably from about 3.5 to about 4.5.  A gelling agent may be added to gel the solution to permit more effective contact of the solution against with the porcelain being treated.
BACKGROUND/AIM: Precision medicine aims to revolutionize healthcare by tailoring treatment regimens. This study aimed to integrate comprehensive tumor genomic profiling (CTGP) by targeted-gene panel sequencing and drug screening by circulating tumor cell-derived organoids (CTOs) into clinical practice for the treatment of gastrointestinal (GI) cancers.
PATIENTS AND METHODS: Nine patients with various GI cancers underwent CTGP and CTO drug sensitivity testing. CTGP results guided targeted therapy and immunotherapy, while CTO drug sensitivity predicted response to chemotherapy and targeted agents. The drug recommendations from two platforms were correlated with the treatment response to the suggested medications retrospectively.
RESULTS: Five patients received therapies aligned with CTGP, including HER2-targeted treatment, immunotherapy, and BRAF/MEK dual inhibition, showing positive responses. CTO drug sensitivity predicted progression under regorafenib (low potential benefit) and good response to chemotherapy with high potential benefit. The combination of CTGP and CTO drug sensitivity may exhibit significant correlation with clinical outcomes during treatment with candidate drugs, demonstrating a sensitivity of 79% and an accuracy of 75%. This encompasses various treatment modalities, such as chemotherapy, targeted therapy, and immunotherapy.
CONCLUSION: The present investigation elucidated the integration of CTGP and CTO drug sensitivity screening into clinical practice in a complementary manner, showcasing a significant correlation between treatment response and testing outcomes. Additional prospective evaluation of these two testing modalities in a large cohort is warranted to confirm whether the inclusion of CTO drug sensitivity screening confers enhanced survival benefits compared to utilizing CTGP alone.
Hemorrhagic progression of contusion (HPC) often occurs early in cerebral contusions (CC) patients, significantly impacting their prognosis. It is vital to promptly assess HPC and predict outcomes for effective tailored interventions, thereby enhancing prognosis in CC patients. We utilized the Attention-3DUNet neural network to semi-automatically segment hematomas from computed tomography (CT) images of 452 CC patients, incorporating 695 hematomas. Subsequently, 1502 radiomic features were extracted from 358 hematomas in 261 patients. After a selection process, these features were used to calculate the radiomic signature (Radscore). The Radscore, along with clinical features such as medical history, physical examinations, laboratory results, and radiological findings, was employed to develop predictive models. For prognosis (discharge Glasgow Outcome Scale score), radiomic features of each hematoma were augmented and fused for correlation. We employed various machine learning methodologies to create both a combined model, integrating radiomics and clinical features, and a clinical-only model. Nomograms based on logistic regression were constructed to visually represent the predictive procedure, and external validation was performed on 170 patients from three additional centers. The results showed that for HPC, the combined model, incorporating hemoglobin levels, Rotterdam CT score of 3, multi-hematoma fuzzy sign, concurrent subdural hemorrhage, international normalized ratio, and Radscore, achieved area under the receiver operating characteristic curve (AUC) values of 0.848 and 0.836 in the test and external validation cohorts, respectively. The clinical model predicting prognosis, utilizing age, Abbreviated Injury Scale for the head, Glasgow Coma Scale Motor component, Glasgow Coma Scale Verbal component, albumin, and Radscore, attained AUC values of 0.846 and 0.803 in the test and external validation cohorts, respectively. Selected radiomic features indicated that irregularly shaped and highly heterogeneous hematomas increased the likelihood of HPC, while larger weighted axial lengths and lower densities of hematomas were associated with a higher risk of poor prognosis. Predictive models that combine radiomic and clinical features exhibit robust performance in forecasting HPC and the risk of poor prognosis in CC patients. Radiomic features complement clinical features in predicting HPC, although their ability to enhance the predictive accuracy of the clinical model for adverse prognosis is limited.
<P>PROBLEM TO BE SOLVED: To provide a retentate chromatography method for separating analytes in a sample.  <P>SOLUTION: The retentate chromatography method includes a process for adsorbing analytes in a substrate under a plurality of different selection conditions and a process for detecting the analytes held in the substrate by desorption spectrometry. The analytes are purified by this and conditions useful for the detection of the analytes are identified. The substrate having an adsorbent is used as specific detector of a plurality of analytes. Impurities are removed by exposing analytes containing impurities to the adsorbent, and the analytes are collected from the adsorbent in a subsequent round. The retentate chromatography method is useful for biology and medicine including clinical diagnosis and chemical discovery.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Longitudinal clinical trials for which recurrent events endpoints are of interest are commonly subject to missing event data. Primary analyses in such trials are often performed assuming events are missing at random, and sensitivity analyses are necessary to assess robustness of primary analysis conclusions to missing data assumptions. Control-based imputation is an attractive approach in superiority trials for imposing conservative assumptions on how data may be missing not at random. A popular approach to implementing control-based assumptions for recurrent events is multiple imputation (MI), but Rubin's variance estimator is often biased for the true sampling variability of the point estimator in the control-based setting. We propose distributional imputation (DI) with corresponding wild bootstrap variance estimation procedure for control-based sensitivity analyses of recurrent events. We apply control-based DI to a type I diabetes trial. In the application and simulation studies, DI produced more reasonable standard error estimates than MI with Rubin's combining rules in control-based sensitivity analyses of recurrent events.
A system and method for providing, managing, and accessing a multi-user secure portable database using secure memory cards is provided. The database has a secure portion for storing security keys and a non-secure portion for encrypted data files. Access to the encrypted data files is controlled by assigning access rights through an access control matrix to each encrypted data file according to a hierarchical structure of users. A user requesting access is identified in the hierarchy, associated with a key for allowing the requested access, and the requested access allowed to a file in accordance with the rights allocated through the access control matrix. A patient can selectively grant access to encrypted medical records on his card to a physician. Authentication of the owner/patient is preferably required. Other records required by emergency medical personnel are readable from the same card without requiring permission from the patient.
Twenty-six Kaiser Permanente Southern California (KPSC) primary care clinics will be randomized in two waves to receive either the TabCAT-BHA paradigm or usual care. Clinics have been matched in pairs by number of providers, median panel size, the racial/ethnic makeup of the patient panel, baseline rates of cognitive impairment diagnosis, rates of telehealth encounters, and percentage of members who are 65+ in the practice. The trial will be conducted over two 18-month waves, with six intervention practices in the first wave and seven intervention practices starting in the second wave. All patients seen at least once across these 26 practices will be included in the trial and the primary analyses will use data extracted from the EMR. Patients in the intervention practices will receive care in accordance with the TabCAT-BHA paradigm whereas patients in the control practices will continue with usual care workflows. The intervention will include a 6-month startup period during which the research team will partner with the physician leads to adapt the paradigm workflows to each practice and onboard the PCPs, and then a 12-month steady state period when effectiveness on the primary and secondary outcomes will be measured. During the TabCAT-BHA paradigm intervention, pragmatically, primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical research associates located in the primary care clinics who will then perform the TabCAT-BHA tablet-based test either on the spot or as a scheduled procedure visit. The tablet-based test provides an automated scoring report that includes guidance for providers to identify reversible causes of cognitive impairment, involving a care partner, diagnostic disclosure, community and educational resources, and specialty referral including the option to refer the patient for a "Brain Health Consultation" telephone call with a study nurse or social worker.
A series of studies on the interventional diagnosis and treatment of tuberculosis(TB)were carried out by domestic and foreign researchers in 2023. The combination of minimally invasive interventional procedures with endoscopes, guidance, material acquisition techniques by multiple ways and multichannel and highly accurate laboratory testing techniques is becoming more and more widely practiced clinically, which has played an important role in the accurate diagnosis of problematic TB. Diagnostic procedures for pulmonary TB, tracheobronchial TB, mediastinal lymphatic TB and extrapulmonary TB included conventional flexible bronchoscopy and specific types of bronchoscopy(ultrathin bronchoscopy and endobronchial ultrasound), transbronchial needle aspiration biopsy, endobronchial ultrasound and virtual bronchoscopic navigation system-guided forceps biopsy, thoracoscopic cryobiopsy of pleura, percutaneous biopsy, and so on. The time to diagnosis has been significantly reduced and the diagnostic efficacy has been improved by the clinical specimen detection using either Gene Xpert MTB/RIF, Ultra, loop-mediated isothermal amplification, metagenomic next-generation sequencing, or nanopore sequencing, etc. Interventional therapy was focused on the following diseases: pulmonary TB with massive hemoptysis, tracheobronchial TB, pleural TB and TB-related fistulas. Interventional treatment of tracheobronchial TB mainly included the application of rigid bronchoscopy, bronchoscopic cold and thermal ablation treatment, endoscopic clamp, dilatations of narrow airway with balloon and stent placement, etc. The interventional treatment of pulmonary TB complicated by massive hemoptysis included endovascular embolization, coated stent placement, etc. Interventional treatment of pleural TB involved the application of thoracoscopy, endoscopic forceps, the implantation of stent and other occlusive devices and the closure of fistulas with autologous fat transplantation. In this article, we reviewed the progress of interventional diagnosis and treatment of TB by the search of published literatures from October 2022 to September 2023.
The invention relates to a fusion cytokine production technology in the technical field of biology, and particularly relates to a method for constructing fusion protein TD-bFGF efficiently expressed in CHO (Chinese Hamster Ovary) cells by means of genetic engineering and application of the fusion protein TD-bFGF. The fusion protein TD-bFGF provided by the invention has an amino acid sequence as shown in SEQ ID No. 2, or has at least 75% of identity compared with the sequence as shown in SEQ ID No. 2. The invention further provides a biological material associated with the fusion protein TD-bFGF and a method for constructing a recombinant bFGF protein in the CHO cells. The TD-bFGF fusion protein obtained by the invention can penetrate the skin, has activity higher than that of the market product, can be used for cosmetic skin medicines, and has effects of reducing the production cost and improving the effect of bFGF; the method constructs CHO cell strains for stably and efficiently expressing a transdermal peptide fragment and cytokine bFGF fusion protein and provides a new application idea for the application of bFGF.